NCT04055753View on ClinicalTrials.gov

Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

Active, not recruitingOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

August 12, 2016

Primary Completion Date

October 15, 2026

Study Completion Date

October 31, 2027

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Doxil

Doxil 50 mg/m2, as per institutional standard

DRUG

Doxorubicin

Doxorubicin 75 mg/m2, IV over 5-15 min OR Continuous infusion over 48-72 hours

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER

NCT04055753 - Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter